Antimicrobial agents and chemotherapy

• 

  Año 2004, Vol. 48, Número 1

  • Growing Group of Extended-Spectrum beta-Lactamases: the CTX-M Enzymes

    R. Bonnet

    págs. 1-14

    

  • Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae

    L. Poirel, C. Heritier

    págs. 15-22

    

  • Escherichia coli Mutators Present an Enhanced Risk for Emergence of Antibiotic Resistance during Urinary Tract Infections

    A. J. O Neill, K. Miller

    págs. 23-29

    

  • High-Throughput Screen for Inhibitors of Transglycosylase and/or Transpeptidase Activities of Escherichia coli Penicillin Binding Protein 1b

    R. K. Shandil, B. Chandrakala

    págs. 30-40

    

  • Effects of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs on Biofilms and Planktonic Cells of Candida albicans

    L. J. Douglas, M. A. S. Alem

    págs. 41-47

    

  • Modeling Antibiotic Tolerance in Biofilms by Accounting for Nutrient Limitation

    M. E. Roberts, P. S. Stewart

    págs. 48-52

    

  • In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and Streptococci

    H. S. Sader, D. M. Johnson

    págs. 53-62

    

  • In Vivo Pharmacodynamic Activity of Daptomycin

    W. A. Craig, D. Andes, N. Safdar

    págs. 63-68

    

  • Anti-Trypanosoma cruzi Activity of Green Tea (Camellia sinensis) Catechins

    M. C. Guida, C. Paveto, M. I. Esteva

    págs. 69-74

    

  • Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: a Novel Approach to Reducing Antimicrobial Resistance

    J. Harmoinen

    págs. 75-79

    

  • Efficacy of BB-83698, a Novel Peptide Deformylase Inhibitor, in a Mouse Model of Pneumococcal Pneumonia

    E. Azoulay Dupuis

    págs. 80-85

    

  • Efficacy of Garenoxacin in Treatment of Experimental Endocarditis Due to Staphylococcus aureus or Viridans Group Streptococci

    J. Vouillamoz, J. M. Entenza, M. P. Glauser

    págs. 86-92

    

  • Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant Pseudomonas aeruginosa

    E. J. Giamarellos Bourboulis

    págs. 93-99

    

  • Oral Delivery of Meglumine Antimoniate-beta-Cyclodextrin Complex for Treatment of Leishmaniasis

    C. Demicheli

    págs. 100-103

    

  • Sensitive Enzyme Immunoassay for Measuring Plasma and Intracellular Nevirapine Levels in Human Immunodeficiency Virus-Infected Patients

    S. Azoulay, M. C. Nevers

    págs. 104-109

    

  • Human Salivary Histatin 5 Fungicidal Action Does Not Induce Programmed Cell Death Pathways in Candida albicans

    D. Wunder

    págs. 110-115

    

  • Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

    R. Wood, H.J. Stellbrink, K. Arasteh

    págs. 116-123

    

  • Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children

    F. M. Balis, A. N. Tullio, R. Hazra

    págs. 124-129

    

  • In Vitro and In Vivo Activities of a Triterpenoid Saponin Extract (PX-6518) from the Plant Maesa balansae against Visceral Leishmania Species

    D. V. Berghe, N. Germonprez, L. Maes

    págs. 130-136

    

  • Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis

    D. Andes, K. Marchillo

    págs. 137-142

    

  • Molecular Basis of Intrinsic Macrolide Resistance in the Mycobacterium tuberculosis Complex

    K. Buriankova, F. Doucet Populaire

    págs. 143-150

    

  • Biofilm Formation by Stenotrophomonas maltophilia: Modulation by Quinolones, Trimethoprim-Sulfamethoxazole, and Ceftazidime

    G. di Bonaventura

    págs. 151-160

    

  • Fungicidal Activity of Fluconazole against Candida albicans in a Synthetic Vagina-Simulative Medium

    M. Y. S. Moosa

    págs. 161-167

    

  • Antimicrobial Susceptibility and Synergy Studies of Stenotrophomonas maltophilia Isolates from Patients with Cystic Fibrosis

    P. S. Gabriel

    págs. 168-171

    

  • Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs

    D. Descamps, V. Joly, G. Peytavin

    págs. 172-175

    

  • Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily

    G. J. Yuen

    págs. 176-182

    

  • Pharmacokinetics and Safety of Single Oral Doses of Emtricitabine in Human Immunodeficiency Virus-Infected Children

    G. E. Chittick, L. H. Wang, A. A. Wiznia, M. H. Rathore

    págs. 183-191

    

  • Five Additional Genes Are Involved in Clavulanic Acid Biosynthesis in Streptomyces clavuligerus

    S. E. Jensen, A. S. Paradkar

    págs. 192-202

    

  • In Vitro Pharmacodynamic Activities of ABT-492, a Novel Quinolone, Compared to Those of Levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

    S. M. Gunderson

    págs. 203-208

    

  • Constitutive Expression of a Chromosomal Class A (BJM Group 2) beta-Lactamase in Xanthomonas campestris

    Y. H. Tseng, S.F. Weng, Y.Y. Chen, C. H. Chen, J. W. Lin

    págs. 209-215